United Therapeutics (UTHR) EBITDA Margin (2009 - 2026)
United Therapeutics (UTHR) reported EBITDA Margin of 45.32% for Q2 2026, down 2.96 percentage points from 48.28% a year earlier but up 0.74 percentage points from the prior quarter.
Powered by 
Analysis
United Therapeutics (UTHR) EBITDA Margin (2009 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, United Therapeutics' EBITDA Margin came in at 47.34%, down 2.30 percentage points year-over-year; for FY2025, it was 49.58%, down 0.79 percentage points from FY2024.
- EBITDA Margin has declined for three consecutive years, though with a five-year change of +6.20 percentage points (FY2020 to FY2025).
- By year, EBITDA Margin came in at 50.38% in FY2024 (-2.82 pp), 53.19% in FY2023 (-0.05 pp), 53.25% in FY2022 (+17.30 pp) and 35.94% in FY2021 (-7.44 pp).
- Five-year quarterly EBITDA Margin spans a low of 38.41% in Q4 2022 and a high of 65.06% in Q1 2022.
- Year over year, EBITDA Margin has now declined in each of the last three quarters, with an average year-over-year change of -1.66 percentage points over the last eight quarters.
- The high point for year-over-year EBITDA Margin in five years was Q1 2022 (a gain of 78.85 percentage points); the low point was Q3 2023 (a drop of 7.57 percentage points).
- Per Business Quant data, the three quarters before Q2 2026 came in at 44.58% (Q1 2026), 48.03% (Q4 2025) and 51.33% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | United Therapeutics | 20.72 Bn | 10.22 Bn | 683.80 Mn | 45.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 45.32% |
| Mar 31, 2026 | 44.58% |
| Dec 31, 2025 | 48.03% |
| Sep 30, 2025 | 51.33% |
| Jun 30, 2025 | 48.28% |
| Mar 31, 2025 | 50.68% |
| Dec 31, 2024 | 51.28% |
| Sep 30, 2024 | 48.36% |
| Jun 30, 2024 | 47.36% |
| Mar 31, 2024 | 54.79% |
| Dec 31, 2023 | 44.54% |
| Sep 30, 2023 | 55.84% |
| Jun 30, 2023 | 54.70% |
| Mar 31, 2023 | 58.73% |
| Dec 31, 2022 | 38.41% |
| Sep 30, 2022 | 63.41% |
| Jun 30, 2022 | 45.94% |
| Mar 31, 2022 | 65.06% |
| Dec 31, 2021 | 43.93% |
| Sep 30, 2021 | 54.22% |
API Access
United Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=UTHR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "UTHR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=UTHR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();